Shire Pharmaceuticals Ireland Limited
GPTKB entity
Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired_by |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:employees |
over 5,000
|
| gptkbp:founded |
gptkb:1986
|
| gptkbp:founder |
Helen O' Neill
|
| gptkbp:headquarters |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shire Pharmaceuticals Ireland Limited
|
| gptkbp:products |
gptkb:Adderall
gptkb:Intuniv gptkb:Vyvanse Fosrenol |
| gptkbp:revenue |
$15 billion (2017)
|
| gptkbp:specializes_in |
rare diseases
|
| gptkbp:subsidiaries |
gptkb:Shire_Development_LLC
gptkb:Shire_International_Gmb_H Shire US Holdings |
| gptkbp:website |
www.shire.com
|
| gptkbp:bfsParent |
gptkb:Shire_Pharmaceuticals
gptkb:Shire_Pharmaceuticals_Group_plc |
| gptkbp:bfsLayer |
6
|